These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. From hypertrophic cardiomyopathy to transthyretin amyloidosis: an unusual case and challenging diagnosis. Petkow-Dimitrow P; Rajtar-Salwa R; Holcman K; Kostkiewicz M; Rubiś P Pol Arch Intern Med; 2020 Feb; 130(2):153-154. PubMed ID: 31933485 [No Abstract] [Full Text] [Related]
10. Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study. Tubben A; Tingen HSA; Prakken NHJ; van Empel VPM; Gorter TM; Meems LMG; Manintveld OC; Rienstra M; Tieleman RG; Glaudemans AWJM; van Veldhuisen DJ; Slart RHJA; Nienhuis HLA; van der Meer P Eur J Heart Fail; 2024 Mar; 26(3):695-698. PubMed ID: 38439596 [No Abstract] [Full Text] [Related]
11. A case report of osteoarthritis associated with hereditary transthyretin amyloidosis ATTRV30M. Anan I; Bång J; Lundgren HE; Wixner J; Westermark P Amyloid; 2019; 26(sup1):29-30. PubMed ID: 31343355 [No Abstract] [Full Text] [Related]
12. Reduced intraepidermal nerve fibre density in patients with hereditary transthyretin amyloidosis. Masuda T; Ueda M; Misumi Y; Nomura T; Inoue Y; Isoguchi A; Kanenawa K; Tasaki M; Yamashita T; Sonoda Y; Obayashi K; Ando Y Amyloid; 2019; 26(sup1):79-80. PubMed ID: 31343297 [No Abstract] [Full Text] [Related]
13. Cardiovascular autonomic functions in late-onset hereditary transthyretin amyloidosis with Val30Met mutation. Nakamura T; Koike H; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Katsuno M; Sobue G Amyloid; 2019; 26(sup1):6. PubMed ID: 31343341 [No Abstract] [Full Text] [Related]
14. Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR. Saelices L; Pokrzywa M; Pawelek K; Eisenberg DS Neurobiol Dis; 2018 Dec; 120():118-125. PubMed ID: 30213731 [TBL] [Abstract][Full Text] [Related]
15. Unexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis. De Pasqual A; Biessaux Y; Blettard N; Crémers S; Caers J Acta Clin Belg; 2013; 68(4):303-5. PubMed ID: 24455802 [TBL] [Abstract][Full Text] [Related]
16. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702 [No Abstract] [Full Text] [Related]
17. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695 [TBL] [Abstract][Full Text] [Related]
18. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. Damy T; Judge DP; Kristen AV; Berthet K; Li H; Aarts J J Cardiovasc Transl Res; 2015 Mar; 8(2):117-27. PubMed ID: 25743445 [TBL] [Abstract][Full Text] [Related]
19. Characterization of untyped cardiac amyloidosis by mass spectrometry in a patient with Gly6Ser transthyretin polymorphism in fatal cardiogenic shock. Damy T; Plante-Bordeneuve V; Dogan A Arch Cardiovasc Dis; 2014 Dec; 107(12):706-8. PubMed ID: 24070596 [No Abstract] [Full Text] [Related]
20. Common clinicopathological features in late-onset hereditary transthyretin amyloidosis (Ala97Gly, Val94Gly and Val30Met). Koike H; Nakamura T; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Yasuda T; Mukai E; Date Y; Shiomi K; Nakazato M; Katsuno M; Sobue G Amyloid; 2019; 26(sup1):24-25. PubMed ID: 31343348 [No Abstract] [Full Text] [Related] [Next] [New Search]